Covey, Todd

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

Wang, M., Rule, S., Zinzani, P. L., Goy, A., Casasnovas, O., Smith, S. D., Damaj, G., Doorduijn, J., Lamy, T., Morschhauser, F., et al. (2018) · The Lancet

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 453

WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection

Yoshida, H., Hamano, S., Senaldi, G., Covey, T., Faggioni, R., Mu, S., Xia, M., Wakeham, A. C., Nishina, H., Potter, J., et al. (2001) · Immunity

T-cell and B-cell ImmunologyCytokine Signaling Pathways and Interactions

Cited by 406

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

Sun, C., Nierman, P., Kendall, E. K., Cheung, J., Gulrajani, M., Herman, S. E. M., Pleyer, C., Ahn, I. E., Stetler-Stevenson, M., Yuan, C. M., et al. (2020) · Blood

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 103